May 14, 2020 / 03:40PM GMT
Ashwani Verma - BofA Merrill Lynch, Research Division - Research Analyst
Good morning, everyone. This session is for CytomX. My name is Ash Verma, and I'm part of the [Smith Capitec and Spec Pharma] team here at Bank of America. And CytomX is a clinical stage biotech company with a focus on cancer immunotherapy. And with me today is Sean McCarthy, Chairman, President and CEO of CytomX. Over to you, Sean.
Sean A. McCarthy - CytomX Therapeutics, Inc. - Chairman, CEO & President
Great. Thank you very much, Ash, and good morning, everyone. Thanks for joining us today. It's a pleasure to be here to provide an update on our recent progress and future directions at CytomX. So moving to Slide 2, our forward-looking statements. I want to remind you that over the next 30 minutes or so, I will be making certain forward-looking statements, and I refer you to our safe harbor statement. Now this has been a very busy year for us at CytomX. We've had many achievements so far this year. And abstracts were, of course, released yesterday for several presentations at ASCO.
CytomX Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers